One BioMed
One BioMed is a Singapore-headquartered private medical diagnostics company founded in 2016 by Mi-Kyoung Park, having raised $5M in 2019 from ARCH Venture Partners, Biopath Ventures, and Seeds Capital.
- Company typePrivate
- Founded2016
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
One BioMed firmographics
Firmographics- Name
- One BioMed
- Website
- https://onebiomed.com
- Company type
- Private
- Founded year
- 2016
- Headcount range
- 11–50 employees
- Short description
- One BioMed is a Singapore-headquartered private medical diagnostics company founded in 2016 by Mi-Kyoung Park, having raised $5M in 2019 from ARCH Venture Partners, Biopath Ventures, and Seeds Capital.
- Ownership category
- akta.pro rank
One BioMed industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Chemistry & Immunoassay Systems (HLAHAAAA)
- akta.pro secondary industries
- Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where One BioMed is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Markets served
One BioMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
One BioMed product offering
Product offeringCore offering
One BioMed is classified as a medical diagnostics company. Specific product lines, test menus, instruments, or service offerings are not enumerated in the available source material; the company's website was inaccessible, and aggregated records list no named products, services, APIs, SDKs, or app offerings. The core offering can therefore only be characterized at the category level as medical diagnostics.
Differentiator
Problem solved
Functional benefit
Companies that use One BioMed
Customer profileIdeal customer profiles1 record
One BioMed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
One BioMed competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Largest in-vitro diagnostics business globally, with deep portfolios in clinical chemistry, immunoassays, and molecular diagnostics. Comparable as the dominant incumbent across all diagnostic modalities One BioMed is likely to serve.
- Hologic: Diversified diagnostics and women's health company with a significant clinical diagnostics business (e.g., Panther systems). Comparable as an established IVD incumbent in clinical laboratory testing.
- BioMérieux: Global leader in in-vitro diagnostics, with a broad portfolio in clinical microbiology, immunoassays, and industrial applications. Comparable as an established IVD player in the same clinical diagnostics segments One BioMed targets.
- QIAGEN: Major provider of molecular diagnostics and sample-preparation technologies for clinical and life-science customers. Comparable as a broad incumbent in molecular and immunoassay-based diagnostic testing.
- Cepheid (Danaher): Molecular diagnostics platform inside Danaher, with a broad installed base of GeneXpert systems in clinical labs and hospitals. Comparable as a large incumbent offering automated clinical diagnostic systems and consumables.
Direct peers
- GenMark Diagnostics: Developer of multiplex molecular diagnostic panels for clinical laboratories. Comparable as a small-cap, technology-focused IVD company competing in clinical diagnostic testing with a similar go-to-market model.
- Meso Scale Diagnostics: Specialty developer of immunoassay and biomarker detection platforms for clinical and research laboratories. Comparable as a focused clinical diagnostics company with assay-and-instrument platform offerings.
- Accelerate Diagnostics: Specialty in-vitro diagnostics company focused on rapid identification of serious pathogens. Comparable as a small-cap clinical diagnostics developer reliant on clinical chemistry and immunoassay-based platforms.
Emerging players
- QuantuMDx: UK-based developer of point-of-care molecular diagnostic devices. Comparable as a smaller, emerging diagnostics platform company pursuing decentralized clinical testing.
Regional players
- MiRXES: Singapore-headquartered molecular diagnostics company developing RNA-based and immunoassay tests. Directly comparable to One BioMed as a Singapore-based diagnostics developer pursuing both IVD and clinical lab channels in Asia.
Market position
Customer concentration
One BioMed social profiles
Digital presenceOne BioMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
One BioMed leadership team
Management profileNumber of profiles
Profiles1 record
One BioMed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
One BioMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about One BioMed
What does One BioMed do?
One BioMed is classified as a medical diagnostics company. Specific product lines, test menus, instruments, or service offerings are not enumerated in the available source material; the company's website was inaccessible, and aggregated records list no named products, services, APIs, SDKs, or app offerings. The core offering can therefore only be characterized at the category level as medical diagnostics.
When was One BioMed founded?
One BioMed was founded in 2016. It employs 11 to 50 people.
Where is One BioMed based?
One BioMed is headquartered in Singapore, Singapore, in the Asia region.
Who are One BioMed's main competitors?
Broad incumbents on record are Roche Diagnostics, Hologic, BioMérieux, QIAGEN and Cepheid (Danaher). Direct peers are GenMark Diagnostics, Meso Scale Diagnostics and Accelerate Diagnostics. QuantuMDx is listed as an emerging player. MiRXES is listed as a regional player.
Does One BioMed have an API?
No public API is recorded for One BioMed.
What industry is One BioMed in?
One BioMed's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAA, Clinical Chemistry & Immunoassay Systems, with a secondary code of HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories. Its NAICS code is 325413 and its SIC code is 8071.